

Alexa B Kimball

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2109916/alexa-b-kimball-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

262
papers

13,618
citations

58
h-index

111
g-index

283
ext. papers

16,120
ext. citations

4.5
avg, IF

6.55
L-index

#	Paper	IF	Citations
262	The Impact of Childhood Atopic Dermatitis on Life Decisions for Caregivers and Families.. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022 ,	4.6	1
261	Hidradenitis Suppurativa Epidemiology 2022 , 10-17		
260	Clinical Evaluation 2022 , 62-68		
259	Transcriptomic analysis of human skin wound healing and rejuvenation following ablative fractional laser treatment. <i>PLoS ONE</i> , 2021 , 16, e0260095	3.7	1
258	Refining how we measure as we test: new insights using adalimumab in patients with hidradenitis suppurativa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 2342	4.6	
257	Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>JAMA Dermatology</i> , 2021 , 157, 301-306	5.1	10
256	A visit guide for hidradenitis suppurativa-Managing a complex disease in a busy clinic. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, e155-e160	4.5	2
255	A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 1147-1161	4.1	0
254	Telehealth Use by Age and Race at a Single Academic Medical Center During the COVID-19 Pandemic: Retrospective Cohort Study. <i>Journal of Medical Internet Research</i> , 2021 , 23, e23905	7.6	8
253	Psoriasis: Knowledge, attitudes and perceptions among primary care providers. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 1421-1423	4.5	1
252	Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 417-421	4.6	3
251	Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. <i>Journal of the American Academy of Dermatology</i> , 2021 ,	4.5	14
250	Impact of Endometriosis on Life-Course Potential: A Narrative Review. <i>International Journal of General Medicine</i> , 2021 , 14, 9-25	2.3	19
249	Plastic Surgical Management of Hidradenitis Suppurativa. <i>Plastic and Reconstructive Surgery</i> , 2021 , 147, 479-491	2.7	1
248	Response to Letter to the Editor entitled: Rethinking biologic and pregnancy research: The importance of assessing postpartum immunosuppression of the infant. <i>International Journal of Women's Dermatology</i> , 2021 , 7, 510-511	2	
247	Hidradenitis suppurativa disease course during pregnancy and postpartum: a retrospective survey study. <i>British Journal of Dermatology</i> , 2021 , 185, 1072-1074	4	1
246	Hidradenitis suppurativa. <i>Nature Reviews Disease Primers</i> , 2020 , 6, 18	51.1	95

245	Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapy. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1215-1218	4.5	13
244	Methotrexate shows benefit in a subset of patients with severe hidradenitis suppurativa. <i>International Journal of Women's Dermatology</i> , 2020 , 6, 159-163	2	5
243	Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice. <i>American Journal of Clinical Dermatology</i> , 2020 , 21, 579-590	7.1	6
242	Biologic therapies for the treatment of hidradenitis suppurativa. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 621-633	5.4	5
241	Publication trends in hidradenitis suppurativa from 2008 to 2018. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 1885-1889	4.6	9
240	Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients. <i>JAAD Case Reports</i> , 2020 , 6, 99-102	1.4	23
239	Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. <i>British Journal of Dermatology</i> , 2020 , 182, 1359-1368	4	14
238	Investigating race and gender in age at onset of hidradenitis suppurativa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, e139-e141	4.6	6
237	Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 936-945	4.5	38
236	Baseline patient-reported outcomes from UNITE: an observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 1302-1308	4.6	7
235	Metabolic dysfunction in human skin: Restoration of mitochondrial integrity and metabolic output by nicotinamide (niacinamide) in primary dermal fibroblasts from older aged donors. <i>Aging Cell</i> , 2020 , 19, e13248	9.9	6
234	What causes hidradenitis suppurativa ?-15 years after. <i>Experimental Dermatology</i> , 2020 , 29, 1154-1170	4	27
233	High placebo rates in clinical trials: Is the problem scoring systems or drug efficacy?. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, e431	4.5	0
232	Burnout Among All Groups of Physicians-Mitigation Strategies for Dermatologists. <i>JAMA Dermatology</i> , 2020 , 156, 1049-1050	5.1	1
231	Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab. <i>British Journal of Dermatology</i> , 2020 , 182, 180-189	4	14
230	Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 117-122	4.5	46
229	TNF- α inhibitors in the treatment of hidradenitis suppurativa. <i>Therapeutic Advances in Chronic Disease</i> , 2019 , 10, 2040622319851640	4.9	17
228	Biologic Treatment for Hidradenitis Suppurativa. <i>American Journal of Clinical Dermatology</i> , 2019 , 20, 625-638	7.1	12

227	North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. <i>Journal of the American Academy of Dermatology</i> , 2019 , 81, 91-101	4.5	102
226	North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management. <i>Journal of the American Academy of Dermatology</i> , 2019 , 81, 76-90	4.5	116
225	Genetic basis for skin youthfulness. <i>Clinics in Dermatology</i> , 2019 , 37, 312-319	3	8
224	Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 1098-1106	4.6	14
223	Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials. <i>British Journal of Dermatology</i> , 2019 , 181, 967-975	4	19
222	Use of biologics in pregnancy: limitations stemming from clinical trials and registry experience. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, e276-e277	4.6	1
221	Reply to: "Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment". <i>Journal of the American Academy of Dermatology</i> , 2019 , 81, e19-e20	4.5	
220	Disease burden and cost of hidradenitis suppurativa: a retrospective examination of US administrative claims data. <i>BMJ Open</i> , 2019 , 9, e030579	3	10
219	Examining the prior authorization process, patient outcomes, and the impact of a pharmacy intervention: A single-center review. <i>Journal of the American Academy of Dermatology</i> , 2019 , 81, 1308-1318	4.5	8
218	Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 19-31	4.6	95
217	Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 333-339	4.6	40
216	Clinical Goals and Barriers to Effective Psoriasis Care. <i>Dermatology and Therapy</i> , 2019 , 9, 5-18	4	44
215	Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 114-119	4.5	31
214	Online communications among hidradenitis suppurativa patients reflect community needs. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 1760-1762	4.5	5
213	Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies. <i>British Journal of Dermatology</i> , 2019 , 180, 1039-1049	4	41
212	Hidradenitis suppurativa for the dermatologic hospitalist. <i>Cutis</i> , 2019 , 104, 276-280	0.4	1
211	Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 1515-1522	4.6	10
210	Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 294-301.e6	4.5	16

209	Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database. <i>Arthritis and Rheumatology</i> , 2018 , 70, 1399-1407	9.5	91
208	Understanding patient engagement in psoriasis treatment. <i>British Journal of Dermatology</i> , 2018 , 178, 988-989	4	3
207	Pharmacoeconomics of Systemic and Biologic Therapy in Dermatology 2018 , 83-91		1
206	Development and initial psychometric evaluation of patient-reported outcome questionnaires to evaluate the symptoms and impact of hidradenitis suppurativa. <i>Journal of Dermatological Treatment</i> , 2018 , 29, 152-164	2.8	20
205	Reliability of the hidradenitis suppurativa clinical response in the assessment of patients with hidradenitis suppurativa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 2254-2256	4.6	11
204	Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. <i>British Journal of Dermatology</i> , 2018 , 179, 615-622	4	39
203	Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>British Journal of Dermatology</i> , 2018 , 179, 984-986	4	6
202	Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2018 , 37, 182-189	1.4	10
201	Adverse Reactions to Biologics in Psoriasis. <i>Current Problems in Dermatology</i> , 2018 , 53, 1-14		11
200	Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 70-80	4.5	51
199	Age-induced and photoinduced changes in gene expression profiles in facial skin of Caucasian females across 6 decades of age. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 29-39.e7	4.5	29
198	AB0912 Two-year efficacy and safety of guselkumab for treatment of moderate-to-severe psoriasis: phase 3 voyage 1 trial 2018 ,		5
197	An assessment of the relative impact of hidradenitis suppurativa, psoriasis, and obesity on quality of life. <i>International Journal of Women's Dermatology</i> , 2018 , 4, 198-202	2	9
196	The Comorbidity Burden of Hidradenitis Suppurativa in the United States: A Claims Data Analysis. <i>Dermatology and Therapy</i> , 2018 , 8, 557-569	4	26
195	Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II. <i>Acta Dermato-Venereologica</i> , 2018 , 98, 932-937	2.2	10
194	Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension. <i>Acta Dermato-Venereologica</i> , 2018 , 98, 98-102	2.2	12
193	Assessment of treatment-seeking behaviour in patients with psoriasis. <i>British Journal of Dermatology</i> , 2018 , 179, 989-990	4	1
192	Adalimumab alleviates skin pain in patients with moderate-to-severe hidradenitis suppurativa: Secondary efficacy results from the PIONEER I and PIONEER II randomized controlled trials. <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 1141-1143	4.5	16

191	Current guidelines for psoriasis treatment: a work in progress. <i>Cutis</i> , 2018 , 101, 10-12	0.4	20
190	Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years. <i>Journal of Drugs in Dermatology</i> , 2018 , 17, 826-832 ^{2,2}		26
189	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 405-417	4.5	476
188	Prevalence and Risk of Inflammatory Bowel Disease in Patients with Hidradenitis Suppurativa. <i>Journal of Investigative Dermatology</i> , 2017 , 137, 1060-1064	4.3	47
187	Understanding the cost of dermatologic care: A survey study of dermatology providers, residents, and patients. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 609-617	4.5	7
186	Itch intensity in moderate-to-severe plaque psoriasis versus atopic dermatitis: A meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 1198-1200.e1	4.5	13
185	Pediatric Psoriasis Comorbidity Screening Guidelines. <i>JAMA Dermatology</i> , 2017 , 153, 698-704	5.1	54
184	Observations from our evaluation of bodyweight changes after initiation of a biologic therapy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, e544-e547	4.6	1
183	Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. <i>Lancet, The</i> , 2017 , 390, 276-288	4.0	302
182	Update on biologic safety for patients with psoriasis during pregnancy. <i>International Journal of Women's Dermatology</i> , 2017 , 3, 21-25	2	58
181	Psoriasis and latitude: Analytic approaches and future data needs. <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, e59	4.5	1
180	Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis. <i>Journal of Dermatological Treatment</i> , 2017 , 28, 716-721	2.8	17
179	The Impact of Administrative Burden on Academic Physicians: Results of a Hospital-Wide Physician Survey. <i>Academic Medicine</i> , 2017 , 92, 237-243	3.9	69
178	Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. <i>British Journal of Dermatology</i> , 2017 , 177, 1401-1409	4	157
177	Unerwünschte Wirkungen von Biologika bei Psoriasis. <i>Karger Kompass Dermatologie</i> , 2017 , 5, 195-199	0	0
176	Comorbidities of hidradenitis suppurativa. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2017 , 36, 55-57	1.4	17
175	A Closer Inspection of the Number Needed to Biopsy-Reply. <i>JAMA Dermatology</i> , 2016 , 152, 953	5.1	
174	Acne Knowledge of Hispanic Parents of Teenagers with Mild to Moderate Acne. <i>Pediatric Dermatology</i> , 2016 , 33, e292-3	1.9	4

173	Targeted Reminder Phone Calls to Patients at High Risk of No-Show for Primary Care Appointment: A Randomized Trial. <i>Journal of General Internal Medicine</i> , 2016 , 31, 1460-1466	4	24
172	Survey on Clinician Perceptions and Practices Regarding Goals of Care Conversations. <i>Journal of Palliative Medicine</i> , 2016 , 19, 1215-1217	2.2	4
171	Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. <i>Drug Safety</i> , 2016 , 39, 755-62	5.1	78
170	The spectrum of nephrocutaneous diseases and associations: Genetic causes of nephrocutaneous disease. <i>Journal of the American Academy of Dermatology</i> , 2016 , 74, 231-44; quiz 245-6	4.5	4
169	The spectrum of nephrocutaneous diseases and associations: Inflammatory and medication-related nephrocutaneous associations. <i>Journal of the American Academy of Dermatology</i> , 2016 , 74, 247-70; quiz 271-2	4.5	4
168	Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States. <i>Journal of the American Academy of Dermatology</i> , 2016 , 74, 190-2	4.5	33
167	Performing research in pregnancy: Challenges and perspectives. <i>Clinics in Dermatology</i> , 2016 , 34, 410-5	3	3
166	Should We Leave the Skin Biopsies to the Dermatologists?. <i>JAMA Dermatology</i> , 2016 , 152, 371-2	5.1	6
165	Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). <i>Journal of the American Academy of Dermatology</i> , 2016 , 74, 851-61.e4	4.5	59
164	Longer-term impact of cardiology e-consults. <i>American Heart Journal</i> , 2016 , 173, 86-93	4.9	34
163	Getting under the Skin: Report from the International Psoriasis Council Workshop on the Role of Stress in Psoriasis. <i>Frontiers in Psychology</i> , 2016 , 7, 87	3.4	11
162	The temporal association between cutaneous T-cell lymphoma and psoriasis: implications for common biologic processes. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016 , 30, e31-e32	4.6	7
161	Effects of TNF-alpha antagonism in patients with metabolic syndrome and psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016 , 30, e152-e154	4.6	2
160	Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy. <i>International Journal of Women's Dermatology</i> , 2016 , 2, 151-153	2	8
159	Systemic causes of hair loss. <i>Annals of Medicine</i> , 2016 , 48, 393-402	1.5	11
158	A novel approach to administration of peptides in women: Systemic absorption of a GnRH agonist via transvaginal ring delivery system. <i>Journal of Controlled Release</i> , 2016 , 233, 19-28	11.7	15
157	Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, 1156-1161	4.5	28
156	Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. <i>New England Journal of Medicine</i> , 2016 , 375, 422-34	59.2	324

155	Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2016 , 175, 157-62	4	51
154	HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016 , 30, 989-94	4.6	79
153	Delivering value in dermatology: insights from skin cancer detection in routine clinical visits. <i>Journal of the American Academy of Dermatology</i> , 2015 , 72, 310-3	4.5	7
152	Psoriasis patients' willingness to accept side-effect risks for improved treatment efficacy. <i>Journal of Dermatological Treatment</i> , 2015 , 26, 507-13	2.8	19
151	Patient navigation based on predictive modeling decreases no-show rates in cancer care. <i>Cancer</i> , 2015 , 121, 1662-70	6.4	29
150	Expanding scope of dermatologic mid-level practitioners includes prescription of complex medication. <i>JAMA Dermatology</i> , 2015 , 151, 106-7	5.1	2
149	Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. <i>New England Journal of Medicine</i> , 2015 , 373, 1318-28	59.2	530
148	Psoriasis and Cardiovascular Disease. <i>Medical Clinics of North America</i> , 2015 , 99, 1227-42	7	21
147	Hidradenitis suppurativa: Epidemiology and scope of the problem. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, S4-7	4.5	123
146	Systemic associations of hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, S27-35	4.5	91
145	Seasonal variation of acne and psoriasis: A 3-year study using the Physician Global Assessment severity scale. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, 523-5	4.5	24
144	Psoriasis and herpes simplex virus are highly stigmatizing compared with other common dermatologic conditions: A survey-based study. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, 525-6	4.5	16
143	Chronic pain management in dermatology: pharmacotherapy and therapeutic monitoring with opioid analgesia. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, 575-82; quiz 583-4	4.5	7
142	Chronic pain management in dermatology: a guide to assessment and nonopioid pharmacotherapy. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, 563-73; quiz 573-4	4.5	14
141	A measure of chronic quality of life predicts socioeconomic and medical outcomes in psoriasis patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29, 249-254	4.6	10
140	Teachable Action for Leaders Committed to Improving Physician Work Life: Continuing Education. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 1455-6	6.4	
139	Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States. <i>British Journal of Dermatology</i> , 2015 , 173, 1183-90	4	28
138	The Utility of Laser Thermometry in Grading Plaque Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2015 , 1, 15-17	1.1	

137	Using the Physician Global Assessment in a clinical setting to measure and track patient outcomes. <i>JAMA Dermatology</i> , 2015 , 151, 375-81	5.1	40
136	OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. <i>Journal of the American Academy of Dermatology</i> , 2015 , 72, 115-22	4.5	51
135	Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis. <i>Journal of the American Academy of Dermatology</i> , 2014 , 71, 1144-50	4.5	181
134	Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory. <i>British Journal of Dermatology</i> , 2014 , 170, 705-15	4	37
133	Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. <i>British Journal of Dermatology</i> , 2014 , 171, 1434-42	4	110
132	Dermatology urgent care: enlisting help from primary care in triage decisions. <i>Journal of the American Academy of Dermatology</i> , 2014 , 71, 838-9	4.5	3
131	Accumulating evidence for the association and shared pathogenic mechanisms between psoriasis and cardiovascular-related comorbidities. <i>American Journal of Medicine</i> , 2014 , 127, 1148-53	2.4	56
130	The relative impact of psoriasis and obesity on socioeconomic and medical outcomes in psoriasis patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014 , 28, 216-21	4.6	12
129	An evaluation of educational debt levels in dermatology residents and effects on career choices. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 1141-2	4.5	1
128	Meta-analysis comparing efficacy of antibiotics versus oral contraceptives in acne vulgaris. <i>Journal of the American Academy of Dermatology</i> , 2014 , 71, 450-9	4.5	40
127	Real-time location systems, normative messaging and modifying clinician behavior: a pilot study. <i>Health Systems</i> , 2014 , 3, 165-172	2.3	2
126	Management of hidradenitis suppurativa wounds with an internal vacuum-assisted closure device. <i>Plastic and Reconstructive Surgery</i> , 2014 , 133, 370e-377e	2.7	26
125	Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial. <i>British Journal of Dermatology</i> , 2014 , 171, 1215-9	4	44
124	Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09. <i>British Journal of Dermatology</i> , 2014 , 170, 366-73	4	38
123	Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). <i>British Journal of Dermatology</i> , 2014 , 171, 137-47	4	89
122	The validity of the diagnostic code for hidradenitis suppurativa in an electronic database. <i>British Journal of Dermatology</i> , 2014 , 171, 338-42	4	23
121	Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014 , 28, 333-7	4.6	134
120	Dermatologic workforce on the Texas border: using burden on primary care as an outcome measure. <i>International Journal of Dermatology</i> , 2013 , 52, 506-7	1.7	1

119	Psoriasis prevalence among the 2009 AAD National Melanoma/Skin Cancer Screening Program participants. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013 , 27, 680-5	4.6	24
118	Psoriasis epidemiology: the interplay of genes and the environment. <i>Journal of Investigative Dermatology</i> , 2013 , 133, 287-9	4.3	64
117	Counterpoint: analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. <i>Journal of the American Academy of Dermatology</i> , 2013 , 69, 818-819	4.5	17
116	OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2013 , 68, 756-64	4.5	26
115	Prevalence of skin disorders in patients seeking health care. <i>Mayo Clinic Proceedings</i> , 2013 , 88, 776	6.4	1
114	Self-reported help-seeking behaviors and treatment choices of adolescents regarding acne. <i>Pediatric Dermatology</i> , 2013 , 30, 36-41	1.9	17
113	Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. <i>JAMA Dermatology</i> , 2013 , 149, 25-32	5.1	98
112	Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013 , 27, 1535-45	4.6	137
111	Cutaneous effects of BRAF inhibitor therapy: a case series. <i>Annals of Oncology</i> , 2013 , 24, 530-537	10.3	60
110	Cumulative life course impairment: evidence for psoriasis. <i>Current Problems in Dermatology</i> , 2013 , 44, 82-90		27
109	Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity. <i>Journal of Dermatological Treatment</i> , 2013 , 24, 255-60	2.8	27
108	Validation of a screening instrument for nephrogenic systemic fibrosis. <i>Arthritis Care and Research</i> , 2013 , 65, 637-42	4.7	2
107	Specializing in accountability: strategies to prepare a subspecialty workforce for care delivery redesign. <i>Academic Medicine</i> , 2013 , 88, 1900-3	3.9	4
106	Treatment of moderate to severe hidradenitis suppurativa. <i>Annals of Internal Medicine</i> , 2013 , 159, 72-3	8	0
105	Beyond the blot: cutting edge tools for genomics, proteomics and metabolomics analyses and previous successes. <i>British Journal of Dermatology</i> , 2012 , 166 Suppl 2, 1-8	4	15
104	Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. <i>Annals of Internal Medicine</i> , 2012 , 157, 846-55	8	255
103	The impact of psoriasis on pregnancy outcomes. <i>Journal of Investigative Dermatology</i> , 2012 , 132, 85-91	4.3	54
102	Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2012 , 66, 369-75	4.5	132

101	Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2012 , 67, 76-85	4.5	80
100	Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2012 , 66, 742-51	4.5	105
99	Teaching empathy to undergraduate medical students using a temporary tattoo simulating psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2012 , 67, 93-9	4.5	8
98	Psoriasis and cardiovascular disease: another contribution in the hierarchy of evidence. <i>British Journal of Dermatology</i> , 2012 , 167, 1198-9	4	1
97	Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. <i>British Journal of Dermatology</i> , 2012 , 166, 861-72	4	95
96	Increased diagnosis of thin superficial spreading melanomas: A 20-year study. <i>Journal of the American Academy of Dermatology</i> , 2012 , 67, 387-94	4.5	49
95	Risks of developing psychiatric disorders in pediatric patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2012 , 67, 651-7.e1-2	4.5	114
94	Skin carotenoid levels are not associated with risk of nonmelanoma skin cancer: response to "Supplement use and the risk of cutaneous squamous cell carcinoma". <i>Journal of the American Academy of Dermatology</i> , 2012 , 67, 1071-2; author reply 1073	4.5	
93	Acne vulgaris in women: prevalence across the life span. <i>Journal of Women's Health</i> , 2012 , 21, 223-30	3	70
92	Association of systemic psoriasis therapies and incidence of myocardial infarction: reply from authors. <i>British Journal of Dermatology</i> , 2012 , 166, 233	4	1
91	Weight loss in obese patients with psoriasis can be successfully achieved during a course of phototherapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012 , 26, 1582-4	4.6	10
90	Latitude and psoriasis prevalence. <i>Journal of the American Academy of Dermatology</i> , 2011 , 65, 870-873	4.5	47
89	Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial. <i>Journal of the American Academy of Dermatology</i> , 2011 , 64, 263-74	4.5	28
88	Meta-analysis of randomized controlled trials using 5% benzoyl peroxide and clindamycin versus 2.5% benzoyl peroxide and clindamycin topical treatments in acne. <i>Journal of the American Academy of Dermatology</i> , 2011 , 65, e117-e119	4.5	14
87	The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. <i>British Journal of Dermatology</i> , 2011 , 165, 1066-73	4	81
86	Economic burden of comorbidities in patients with psoriasis is substantial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011 , 25, 157-63	4.6	83
85	Skin carotenoid levels in adult patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011 , 25, 945-9	4.6	18
84	Comparison of the epidemiology of acne vulgaris among Caucasian, Asian, Continental Indian and African American women. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011 , 25, 1054-60	4.6	77

83	Re. major life-changing decisions and cumulative life course impairment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011 , 25, 246-246	4.6	4
82	Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. <i>American Journal of Clinical Dermatology</i> , 2011 , 12, 51-62	7.1	35
81	Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 306, 864-71	27.4	202
80	Psoriasis: is the impairment to a patient's life cumulative?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010 , 24, 989-1004	4.6	127
79	Assessing dermatology board examination competence using questions distribution: a 12-year Brazilian experience. <i>International Journal of Dermatology</i> , 2010 , 49, 1080-2	1.7	1
78	Reduction in the appearance of facial hyperpigmentation after use of moisturizers with a combination of topical niacinamide and N-acetyl glucosamine: results of a randomized, double-blind, vehicle-controlled trial. <i>British Journal of Dermatology</i> , 2010 , 162, 435-41	4	48
77	OBSERVE-5, an Observational Post-Marketing Safety Surveillance Registry of Etanercept for the Treatment of Psoriasis: A Model for Studying New Psoriasis Therapies. <i>Psoriasis Forum</i> , 2010 , 16a, 3-7		3
76	Meta-analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne. <i>Journal of the American Academy of Dermatology</i> , 2010 , 63, 52-62	4.5	47
75	Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. <i>Journal of the American Academy of Dermatology</i> , 2010 , 63, 457-65	4.5	139
74	Health disparities among different ethnic and racial middle and high school students in sun exposure beliefs and knowledge. <i>Journal of Adolescent Health</i> , 2010 , 47, 106-9	5.8	21
73	Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream. <i>American Journal of Clinical Dermatology</i> , 2010 , 11, 275-83	7.1	13
72	A cost-effectiveness comparison of liquor carbonis distillate solution and calcipotriol cream in the treatment of moderate chronic plaque psoriasis. <i>Archives of Dermatology</i> , 2010 , 146, 919-22		2
71	Self-reported acne severity, treatment, and belief patterns across multiple racial and ethnic groups in adolescent students. <i>Pediatric Dermatology</i> , 2010 , 27, 446-52	1.9	37
70	Targeting IL-23: insights into the pathogenesis and the treatment of psoriasis. <i>Indian Journal of Dermatology</i> , 2010 , 55, 171-5	0.9	10
69	Melanoma in Hong Kong between 1983 and 2002: a decreasing trend in incidence observed in a complex socio-political and economic setting. <i>Melanoma Research</i> , 2010 , 20, 427-30	3.3	7
68	Text-message reminders to improve sunscreen use: a randomized, controlled trial using electronic monitoring. <i>Archives of Dermatology</i> , 2009 , 145, 1230-6		173
67	Briakinumab. <i>Expert Opinion on Biological Therapy</i> , 2009 , 9, 1107-13	5.4	33
66	Socioeconomic disability in psoriasis. <i>British Journal of Dermatology</i> , 2009 , 161, 1410-2	4	7

65	Long-term safety of biologics in dermatology. <i>Dermatologic Therapy</i> , 2009 , 22, 2-21	2.2	7
64	The burden of autoimmune disease: a comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2009 , 61, 405-10	4.5	81
63	Patient preferences for dermatology visits. <i>Journal of the American Academy of Dermatology</i> , 2009 , 61, 1083-4	4.5	1
62	Pregnancy outcomes in psoriasis: why do we know so little?. <i>Journal of the American Academy of Dermatology</i> , 2009 , 61, e5-8	4.5	30
61	New antifungal therapies for the treatment of onychomycosis. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 727-34	5.9	39
60	Survey research in dermatology: guidelines for success. <i>Dermatologic Clinics</i> , 2009 , 27, 121-31, vi	4.2	8
59	Impact of Film ("My Skin's on Fire: Living With Psoriasis") on Medical Student Education in Dermatology. <i>Journal of the Dermatology Nurses Association</i> , 2009 , 1, 190-194	0.2	
58	Skin differences, needs, and disorders across global populations. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2008 , 13, 2-5	1.1	9
57	Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. <i>Value in Health</i> , 2008 , 11, 400-7	3.3	45
56	A single-blinded, randomized pilot study to evaluate the effect of exercise-induced sweat on truncal acne. <i>Pediatric Dermatology</i> , 2008 , 25, 126-8	1.9	11
55	Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 106-15	4.5	685
54	Who else is providing care in dermatology practices? Trends in the use of nonphysician clinicians. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 211-6	4.5	65
53	Fate of manuscripts declined by the Journal of the American Academy of Dermatology. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 632-5	4.5	31
52	Acne and oral contraceptives: update on women's health screening guidelines. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 781-6	4.5	18
51	National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 1031-42	4.5	329
50	Rethinking eligibility creep. <i>Journal of the American Academy of Dermatology</i> , 2008 , 59, 165-7; author reply 167	4.5	1
49	The US dermatology workforce: a specialty remains in shortage. <i>Journal of the American Academy of Dermatology</i> , 2008 , 59, 741-5	4.5	176
48	Cutaneous manifestations of thyroid disease. <i>Clinics in Dermatology</i> , 2008 , 26, 283-7	3	45

47	Future perspectives/quo vadis psoriasis treatment? Immunology, pharmacogenomics, and epidemiology. <i>Clinics in Dermatology</i> , 2008 , 26, 554-61	3	5
46	Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). <i>Lancet, The</i> , 2008 , 371, 1665-74	4.0	1296
45	Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. <i>Archives of Dermatology</i> , 2008 , 144, 200-7		179
44	Quality of life and treatment satisfaction among patients with psoriasis and psoriatic arthritis and patients with psoriasis only : results of the 2005 Spring US National Psoriasis Foundation Survey. <i>American Journal of Clinical Dermatology</i> , 2008 , 9, 111-7	7.1	40
43	Targeting the IL-12/IL-23 cytokine family in the treatment of psoriatic disease. <i>Expert Review of Dermatology</i> , 2008 , 3, 453-463		2
42	Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002. <i>Dermatology</i> , 2008 , 217, 27-37	4.4	135
41	Clobetasol propionate emollient formulation foam in the treatment of corticosteroid-responsive dermatoses. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 2001-7	4	7
40	Ketoconazole 2% foam for treatment of seborrheic dermatitis. <i>Expert Review of Dermatology</i> , 2008 , 3, 15-21		2
39	US dermatology residents' satisfaction with training and mentoring: survey results from the 2005 and 2006 Las Vegas Dermatology Seminars. <i>Archives of Dermatology</i> , 2008 , 144, 896-900		26
38	Treatment Satisfaction and Health-related Quality of Life among Individuals with Psoriasis: National Psoriasis Foundation Survey Findings. <i>Psoriasis Forum</i> , 2008 , 14a, 27-34		1
37	Advances in the treatment of acne. <i>Journal of reproductive medicine, The</i> , 2008 , 53, 742-52		5
36	Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2007 , 18, 341-50	2.8	72
35	Leadership workforce in academic dermatology. <i>Archives of Dermatology</i> , 2007 , 143, 948-9		3
34	Psoriasis and psoriatic arthritis: separate or one and the same?. <i>British Journal of Dermatology</i> , 2007 , 157, 850-60	4	42
33	Innovative care, medical research, and the ethics of informed consent. <i>Journal of the American Academy of Dermatology</i> , 2007 , 56, 330-2	4.5	
32	Reporting of ethical review of clinical research submitted to the Journal of the American Academy of Dermatology. <i>Journal of the American Academy of Dermatology</i> , 2007 , 56, 279-84	4.5	11
31	Practice patterns among osteopathic dermatologists in the United States. <i>Journal of the American Academy of Dermatology</i> , 2007 , 56, 524-5	4.5	7
30	Skin sun-acne tutorial evaluation among middle- and high-school students in central New Jersey. <i>Journal of the American Academy of Dermatology</i> , 2007 , 56, 407-12	4.5	10

29	Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001-2002. <i>Current Medical Research and Opinion</i> , 2006 , 22, 989-1000	2.5	76
28	IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. <i>Journal of Experimental Medicine</i> , 2006 , 203, 2577-87	16.6	524
27	Controlled nail trephination for subungual hematoma. <i>American Journal of Emergency Medicine</i> , 2006 , 24, 875-7	2.9	27
26	Striae gravidarum. <i>Clinics in Dermatology</i> , 2006 , 24, 97-100	3	49
25	Rising educational debt levels in recent dermatology trainees and effects on career choices. <i>Journal of the American Academy of Dermatology</i> , 2006 , 54, 329-31	4.5	10
24	Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2006 , 55, 607-13	4.5	149
23	Few Medicaid and uninsured patients are accessing dermatologists. <i>Journal of the American Academy of Dermatology</i> , 2006 , 55, 1084-8	4.5	45
22	Accessibility to air travel correlates strongly with increasing melanoma incidence. <i>Melanoma Research</i> , 2006 , 16, 77-81	3.3	42
21	Medical versus surgical dermatology: how much training do residents receive?. <i>Dermatologic Surgery</i> , 2006 , 32, 597	1.7	6
20	How low should you go: novel device for nail trephination. <i>Dermatologic Surgery</i> , 2006 , 32, 828-33	1.7	9
19	A single-blinded, randomized, controlled clinical trial evaluating the effect of face washing on acne vulgaris. <i>Pediatric Dermatology</i> , 2006 , 23, 421-7	1.9	44
18	Striae and pelvic relaxation: two disorders of connective tissue with a strong association. <i>Journal of Investigative Dermatology</i> , 2006 , 126, 1745-8	4.3	29
17	An assessment of the cost-utility of therapy for psoriasis. <i>Therapeutics and Clinical Risk Management</i> , 2006 , 2, 325-8	2.9	7
16	The psychosocial burden of psoriasis. <i>American Journal of Clinical Dermatology</i> , 2005 , 6, 383-92	7.1	324
15	Clobetasol propionate foam in the treatment of psoriasis. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 1735-40	4	13
14	Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased. <i>British Journal of Dermatology</i> , 2004 , 151, 381-7	4	70
13	Workforce characteristics of mohs surgery fellows. <i>Dermatologic Surgery</i> , 2004 , 30, 136-8; discussion 138	1.7	11
12	The dermatology workforce shortage. <i>Journal of the American Academy of Dermatology</i> , 2004 , 50, 50-4	4.5	110

11	The dermatology life quality index (DLQI) provides qualitatively different information from the pasi. <i>Journal of the American Academy of Dermatology</i> , 2004 , 50, P156	4.5	5
10	Gender and parenting significantly affect work hours of recent dermatology program graduates. <i>Archives of Dermatology</i> , 2004 , 140, 191-6		25
9	Eruptive xanthomas associated with olanzapine use. <i>Archives of Dermatology</i> , 2003 , 139, 1045-8		19
8	Topical vitamins, minerals and botanical ingredients as modulators of environmental and chronological skin damage. <i>British Journal of Dermatology</i> , 2003 , 149, 681-91	4	92
7	Dermatology: a unique case of specialty workforce economics. <i>Journal of the American Academy of Dermatology</i> , 2003 , 48, 265-70	4.5	27
6	The response of skin disease to stress: changes in the severity of acne vulgaris as affected by examination stress. <i>Archives of Dermatology</i> , 2003 , 139, 897-900		131
5	Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10. <i>Archives of Dermatology</i> , 2002 , 138, 1341-6		51
4	Diffuse morbilliform eruption after consumption of ginkgo biloba supplement. <i>Journal of the American Academy of Dermatology</i> , 2002 , 46, 145-6	4.5	16
3	Quantifying the harmful effect of psoriasis on health-related quality of life. <i>Journal of the American Academy of Dermatology</i> , 2002 , 47, 512-8	4.5	207
2	Cytarabine-induced acute generalized exanthematous pustulosis. <i>Journal of the American Academy of Dermatology</i> , 2002 , 47, 633-5	4.5	9
1	Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy. <i>Arthritis and Rheumatism</i> , 2000 , 43, 1866-73		111